| 张伟 王刚 陈明 范萍 夏泉 叶科峰 王达理.阿托伐他汀对急性冠脉综合征患者血脂蛋白相关磷脂酶A2 的影响[J].,2015,15(21):4094-4097 |
| 阿托伐他汀对急性冠脉综合征患者血脂蛋白相关磷脂酶A2 的影响 |
| Effect of Atorvastatin on Lipoprotein Associated Phospholipase A2 inPatients with Acute Coronary Syndrome |
| |
| DOI： |
| 中文关键词: 阿托伐他汀 急性冠脉综合征 血脂蛋白相关磷脂酶A2 |
| 英文关键词: Atovatatin Acute coronary syndrome Serumlipoprotein associated phospholipase A2 |
| 基金项目:国家自然科学基金项目（81160029） |
|
| 摘要点击次数: 490 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探究阿托伐他汀对急性冠脉综合征（Acute Coronary Syndrome，ACS）患者血脂蛋白相关磷脂酶A2 的影响。方法：选取
我院2013 年12 月到2014 年11 月收治的急性冠脉综合征患者50 例，随机分为两组，其中对照组给予常规药物治疗，实验组予
以阿托伐他汀治疗。观察并比较两组患者的临床疗效及血清Lp-PLA2水平的变化情况。结果：经药物干预后，血脂各项指标（TG、
TC、HDL-C、LDL-C）均显著下降，与治疗前相比，差异具有统计学意义（P＜ 0.05），治疗后实验组与对照组相比，血脂各项指标下降
更为明显，差异具有统计学意义（P＜ 0.05）；治疗后两组患者的血清Lp-PLA2 水平与治疗前均显著下降，经统计学分析，差异具有
统计学意义（P<0.05），治疗后与对照组相比，实验组下降更为显著，差异具有统计学意义（P<0.05）。结论：阿托伐他汀可以明显改
善ACS 患者的各临床症状，降低血脂及血清Lp-PLA2 水平，为治疗ACS 的首选方法。 |
| 英文摘要: |
| Objective:To study the effects of atorvastatin on lipoprotein associated phospholipase A2 in patients with acute coronary
syndrome.Methods:20 cases of patients with acute coronary syndrome were selected in our hospital from December 2013 to
November 2014, then they were randomly divided into two groups, 25 patients in control group received conventional drugs, 25 cases in
the experimental group, which were given atorvastatin tablets (Pfizer Inc) in 40 mg by oral, once per night for 7 days. After the end of
treatment, the clinical curative effect and the level of serum Lp-PLA2 were detected and compared between two groups.Results:After
drug intervention, the indexes of blood lipid (TG, TC, HDL-C, LDL-C) were significantly decreased, compared with that before treatment,
with significant difference (P<0.05), and the indexes of blood lipid were decreased more obviously in experimental group than control
group with statistical significance (P<0.05). After the treatment, the serum level of Lp-PLA2 of two groups were significantly decreased,
with statistical difference compared to before treatment (P<0.05); After treatment, compared with control group, the Lp-PLA2
was decreased more significantly with significant difference (P<0.05).Conclusion:Atorvastatin can significantly improve the clinical
symptoms of ACS patients, decrease blood lipid and serum Lp-PLA2 level, and can be used as the first choice in the treatment of ACS in
clinic. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
